MIRA Pharmaceuticals reports positive proof-of-concept results for obesity drug SKNY-1

MIRA Pharmaceuticals announced initial proof-of-concept results from a pilot study of SKNY-1 for obesity and metabolic disorders in a diet-induced obesity mouse model, showing statistically significant reductions in body weight and fat mass after oral administration versus vehicle-treated controls.

Detected & updated continuously · Source: Nebula